News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
874,333 Results
Type
Article (88222)
Company Profile (733)
Press Release (785353)
Multimedia
Podcasts (216)
Webinars (34)
Section
Business (233354)
Career Advice (4153)
Deals (39913)
Drug Delivery (161)
Drug Development (91481)
Employer Resources (206)
FDA (18450)
Job Trends (17454)
News (398131)
Policy (39976)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (3031)
Academic (1)
Accelerated approval (45)
Adcomms (35)
Allergies (170)
Alliances (56973)
ALS (206)
Alzheimer's disease (1876)
Antibody-drug conjugate (ADC) (412)
Approvals (18691)
Artificial intelligence (685)
Autoimmune disease (244)
Automation (52)
Bankruptcy (407)
Best Places to Work (12617)
BIOSECURE Act (23)
Biosimilars (219)
Biotechnology (453)
Bladder cancer (182)
Brain cancer (71)
Breast cancer (718)
Cancer (5592)
Cardiovascular disease (489)
Career advice (3582)
Career pathing (46)
CAR-T (327)
CDC (66)
Celiac Disease (2)
Cell therapy (886)
Cervical cancer (43)
Clinical research (77756)
Collaboration (2063)
Company closure (6)
Compensation (1299)
Complete response letters (89)
COVID-19 (3007)
CRISPR (110)
C-suite (1039)
Cystic fibrosis (158)
Data (7235)
Decentralized trials (3)
Denatured (81)
Depression (172)
Dermatology (59)
Diabetes (569)
Diagnostics (7386)
Digital health (54)
Diversity (13)
Diversity, equity & inclusion (49)
Drug discovery (334)
Drug pricing (223)
Drug shortages (35)
Duchenne muscular dystrophy (283)
Earnings (101141)
Editorial (70)
Employer branding (25)
Employer resources (174)
Events (136179)
Executive appointments (1091)
FDA (21973)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (30)
Funding (1714)
Gene editing (237)
Generative AI (64)
Gene therapy (742)
GLP-1 (1168)
Government (5474)
Grass and pollen (7)
Guidances (398)
Healthcare (20973)
HIV (77)
Huntington's disease (58)
IgA nephropathy (96)
Immunology and inflammation (321)
Immuno-oncology (92)
Indications (158)
Infectious disease (3338)
Inflammatory bowel disease (222)
Inflation Reduction Act (17)
Influenza (135)
Intellectual property (281)
Interviews (817)
IPO (17965)
IRA (58)
Job creations (5204)
Job search strategy (2869)
JPM (72)
Kidney cancer (19)
Labor market (104)
Layoffs (665)
Leadership (45)
Legal (10155)
Liver cancer (106)
Longevity (29)
Lung cancer (752)
Lymphoma (416)
Machine learning (54)
Management (66)
Manufacturing (990)
MASH (194)
Medical device (15093)
Medtech (15174)
Mergers & acquisitions (23089)
Metabolic disorders (1543)
mRNA (216)
Multiple sclerosis (180)
NASH (24)
Neurodegenerative disease (430)
Neuropsychiatric disorders (112)
Neuroscience (3382)
Neurotech (1)
NextGen: Class of 2026 (7693)
Non-profit (5125)
Now hiring (74)
Obesity (746)
Opinion (353)
Ovarian cancer (190)
Pain (243)
Pancreatic cancer (267)
Parkinson's disease (358)
Partnered (37)
Patents (575)
Patient recruitment (617)
Peanut (65)
People (67307)
Pharmaceutical (129)
Pharmacy benefit managers (35)
Phase 1 (24026)
Phase 2 (33774)
Phase 3 (25418)
Pipeline (7266)
Policy (362)
Postmarket research (3553)
Preclinical (10779)
Press Release (72)
Prostate cancer (284)
Psychedelics (60)
Radiopharmaceuticals (326)
Rare diseases (1101)
Real estate (7445)
Recruiting (81)
Regulatory (29591)
Reports (73)
Research institute (2744)
Resumes & cover letters (653)
Rett syndrome (33)
RNA editing (22)
RSV (88)
Schizophrenia (177)
Series A (291)
Series B (213)
Service/supplier (27)
Sickle cell disease (115)
Special edition (29)
Spinal muscular atrophy (185)
Sponsored (52)
Startups (4348)
State (2)
Stomach cancer (20)
Supply chain (122)
Tariffs (97)
The Weekly (132)
Vaccines (1207)
Venture capital (111)
Weight loss (500)
Women's health (114)
Worklife (23)
Date
Today (130)
Last 7 days (693)
Last 30 days (2868)
Last 365 days (31758)
2026 (8434)
2025 (31965)
2024 (37616)
2023 (42567)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51337)
2018 (39122)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1291)
Alabama (99)
Alaska (7)
Arizona (367)
Arkansas (15)
Asia (51822)
Australia (9102)
California (12693)
Canada (3582)
China (1319)
Colorado (545)
Connecticut (545)
Delaware (376)
Europe (119173)
Florida (1892)
Georgia (411)
Hawaii (4)
Idaho (69)
Illinois (1032)
India (87)
Indiana (577)
Iowa (24)
Japan (499)
Kansas (138)
Kentucky (48)
Louisiana (43)
Maine (78)
Maryland (1562)
Massachusetts (9244)
Michigan (365)
Minnesota (709)
Mississippi (7)
Missouri (143)
Montana (36)
Nebraska (30)
Nevada (141)
New Hampshire (88)
New Jersey (3400)
New Mexico (32)
New York (3356)
North Carolina (1721)
North Dakota (10)
Northern California (6202)
Ohio (382)
Oklahoma (25)
Oregon (52)
Pennsylvania (2539)
Puerto Rico (27)
Rhode Island (52)
South America (1667)
South Carolina (76)
South Dakota (1)
Southern California (4949)
Tennessee (202)
Texas (2006)
United States (45385)
Utah (382)
Vermont (1)
Virginia (309)
Washington D.C. (86)
Washington State (1038)
West Virginia (4)
Wisconsin (127)
Wyoming (2)
874,333 Results for "bio path holdings inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Huntington’s disease
UniQure’s Path for Huntington’s Gene Therapy Clouded by Ethical Questions as Potential Phase 3 Looms
While the FDA appears to be adamant that uniQure conduct a sham surgery–controlled Phase 3 trial before AMT-130 can be considered for approval, experts believe there is an alternate path forward for the therapy, perhaps even based on precedent from the recent drama surrounding Moderna’s mRNA flu vaccine.
March 5, 2026
·
7 min read
·
Heather McKenzie
Immunology and inflammation
Ocular’s Hydrogel Beats Regeneron’s Eylea in Wet AMD Study, Plots Path to FDA
Following the successful late-stage study in wet age-related macular degeneration, Ocular plans to meet with the FDA to determine a regulatory path for Axpaxli.
February 17, 2026
·
2 min read
·
Tristan Manalac
Policy
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24
Dallas, Texas--(Newsfile Corp. - June 4, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q1 2024.
June 4, 2024
·
1 min read
Press Releases
Bio-Path Holdings Provides Clinical and Operational Update
June 4, 2025
·
8 min read
Press Releases
INmune Bio Inc. Announces 2025 Results and Provides Business Update
March 30, 2026
·
15 min read
Press Releases
Applied StemCell and Cellipont Bioservices Partner to Offer a Seamless Path for iPSC-Derived Cell Therapy Development
March 24, 2026
·
4 min read
Press Releases
Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum
June 9, 2025
·
3 min read
Immuno-oncology
Replimune Crashes as Uncertainty Clouds Regulatory Path for Tumor Destroyer
Investors had been “holding out hope” that there remained a regulatory path forward for RP1, but results of Replimune’s Type A meeting with the FDA do not appear to support this, according to BMO Capital Markets.
September 19, 2025
·
2 min read
·
Tristan Manalac
IgA nephropathy
Vertex’s Nephropathy Asset Delivers ‘Strong’ Late-Stage Data, Clears Path to FDA
Vertex Pharmaceuticals has a rolling biologics license application with the FDA for povetacicept in IgA nephropathy. With new data from RAINIER, the biotech expects to complete its submission by the end of March.
March 10, 2026
·
2 min read
·
Tristan Manalac
Business
Bio-Path Holdings Reports First Quarter 2024 Financial Results
Bio-Path Holdings, Inc. announced its financial results for the first quarter ended March 31, 2024 and provided an update on recent corporate developments.
May 15, 2024
·
7 min read
1 of 87,434
Next
